Observers had been anticipating Alizyme PLC 's first out-licensing deal for most of 2003 but the firm's August agreement with Takeda Pharmaceutical Co. Ltd. for Japanese rights to Alizyme's obesity treatment ATL-962 surprised some analysts [See Deal].
Alizyme/Takeda: Japan Deals Gather Steam
Alizyme's out-licensing pact with Takeda for Japanese rights to the UK biotech's Phase II anti-obesity compound ATL-962 underscores the practical and funding advantages of a Japanese-market deal as a precursor to negotiating US and European licenses. Opportunities for other European biotechs to do the same may increase: Takeda's willingness to develop a still relatively early-stage compound in a tricky development area highlights Japanese firms' particularly acute need for pipeline products.
More from Global Vision
The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.
New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.
China's medical equipment industry is growing rapidly, driven by limited domestic presence in high-cost segments and increasing adoption of local products in areas like monitoring equipment, defibrillators, and ventilators. International giants dominate the high-end market, but domestic companies such as Neusoft Medical Systems and Mindray Medical are making significant strides.
Close collaboration between industry, academia and government in employing artificial intelligence could solve the looming threat of antimicrobial resistance, a new report co-authored by Google says.
More from In Vivo
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.